OncLive SOSS

Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice - Episode 6

Other Frontline Immunotherapy-based Combinations in Advanced HCC

March 6, 2023

Michael A. Morse, MD, Nicole Rich, MD, Pierre Gholam, MD, Daneng Li, MD, Arndt Vogel, MD

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Patients With Intermediate Stage HCC Unsuitable for TACE

EP. 2: Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

EP. 3: Patients With Intermediate Stage HCC Suitable for TACE

EP. 4: HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

EP. 5: Selecting the Appropriate Frontline Treatment in Advanced HCC

EP. 6: Other Frontline Immunotherapy-based Combinations in Advanced HCC

EP. 7: Patient Profile 2: Advanced HCC Treated with Lenvatinib

EP. 8: Real-World Evidence for Lenvatinib in Advanced HCC

EP. 9: Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

EP. 10: Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

EP. 11: Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

EP. 12: Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

EP. 13: Treatment Considerations for Advanced HCC in Second Line and Beyond

EP. 14: Management of Child-Pugh B Patients with Advanced HCC

EP. 15: Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

x